CALIWAY BIOPHARMACEUTICALS CO L
Caliway Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the development of drugs for aesthetic medicine and chronic inflammation. The company develops CBL-514, an investigational drug, which is in Phase 2 clinical trial for non-surgical fat reduction and Dercum's disease, as well as for cellulite treatment. It is also developing CBA-539, which is in preclinical stage for … Read more
Market Cap & Net Worth: CALIWAY BIOPHARMACEUTICALS CO L (6919)
CALIWAY BIOPHARMACEUTICALS CO L (TW:6919) has a market capitalization of $5.68 Billion (NT$187.91 Billion) as of March 18, 2026. Listed on the TW stock exchange, this Taiwan-based company holds position #3146 globally and #64 in its home market, demonstrating a -15.09% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CALIWAY BIOPHARMACEUTICALS CO L's stock price NT$121.00 by its total outstanding shares 1552977000 (1.55 Billion).
CALIWAY BIOPHARMACEUTICALS CO L Market Cap History: 2024 to 2026
CALIWAY BIOPHARMACEUTICALS CO L's market capitalization history from 2024 to 2026. Data shows growth from $28.87 Billion to $5.68 Billion (0.00% CAGR).
CALIWAY BIOPHARMACEUTICALS CO L Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CALIWAY BIOPHARMACEUTICALS CO L's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
649.65x
CALIWAY BIOPHARMACEUTICALS CO L's market cap is 649.65 times its annual revenue
1742.66x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2024 | $28.87 Billion | $44.43 Million | -$588.83 Million | 649.65x | N/A |
Competitor Companies of 6919 by Market Capitalization
Companies near CALIWAY BIOPHARMACEUTICALS CO L in the global market cap rankings as of March 18, 2026.
Key companies related to CALIWAY BIOPHARMACEUTICALS CO L by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #158 globally with a market cap of $118.01 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.58 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #158 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $118.01 Billion | $466.10 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.58 Billion | $756.91 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
CALIWAY BIOPHARMACEUTICALS CO L Historical Marketcap From 2024 to 2026
Between 2024 and today, CALIWAY BIOPHARMACEUTICALS CO L's market cap moved from $28.87 Billion to $ 5.68 Billion, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$5.68 Billion | -21.94% |
| 2025 | NT$7.28 Billion | -74.80% |
| 2024 | NT$28.87 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of CALIWAY BIOPHARMACEUTICALS CO L was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.68 Billion USD |
| MoneyControl | $5.68 Billion USD |
| MarketWatch | $5.68 Billion USD |
| marketcap.company | $5.68 Billion USD |
| Reuters | $5.68 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.